AU2019363610B2 - Soluble extracellular matrix composition and method for intravascular delivery - Google Patents
Soluble extracellular matrix composition and method for intravascular deliveryInfo
- Publication number
- AU2019363610B2 AU2019363610B2 AU2019363610A AU2019363610A AU2019363610B2 AU 2019363610 B2 AU2019363610 B2 AU 2019363610B2 AU 2019363610 A AU2019363610 A AU 2019363610A AU 2019363610 A AU2019363610 A AU 2019363610A AU 2019363610 B2 AU2019363610 B2 AU 2019363610B2
- Authority
- AU
- Australia
- Prior art keywords
- soluble
- composition
- ecm
- solmm
- infusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862750303P | 2018-10-25 | 2018-10-25 | |
| US62/750,303 | 2018-10-25 | ||
| PCT/US2019/058052 WO2020086955A1 (en) | 2018-10-25 | 2019-10-25 | Soluble extracellular matrix composition and method for intravascular delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019363610A1 AU2019363610A1 (en) | 2021-05-13 |
| AU2019363610B2 true AU2019363610B2 (en) | 2025-11-13 |
Family
ID=70330739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019363610A Active AU2019363610B2 (en) | 2018-10-25 | 2019-10-25 | Soluble extracellular matrix composition and method for intravascular delivery |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210379245A1 (https=) |
| EP (1) | EP3870192A4 (https=) |
| JP (2) | JP7536004B2 (https=) |
| CN (1) | CN112867499A (https=) |
| AU (1) | AU2019363610B2 (https=) |
| CA (1) | CA3117688A1 (https=) |
| WO (1) | WO2020086955A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230364152A1 (en) * | 2020-09-14 | 2023-11-16 | The Regents Of The University Of California | Compositions and methods of use for infusible extracellular matrix |
| CN121195059A (zh) * | 2023-04-06 | 2025-12-23 | 株式会社Medifab | 基于超临界二氧化碳工艺的水溶性脱细胞基质 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170049932A1 (en) * | 2014-04-24 | 2017-02-23 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fractionating Extracellular Matrix to Modulate Bioactivity and the Host Response |
| WO2018161034A1 (en) * | 2017-03-02 | 2018-09-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Extracellular matrix (ecm) hydrogel and soluble fraction thereof for the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2808225C (en) * | 2010-08-24 | 2019-02-12 | The Regents Of The University Of California | Compositions and methods for cardiac therapy |
| KR101628821B1 (ko) * | 2015-03-02 | 2016-06-13 | 강원대학교산학협력단 | 탈세포화된 생체 조직 유래의 생체적합성 가용화 스캐폴드 추출물, 이의 제조방법 및 이의 용도 |
| US11406736B2 (en) * | 2016-01-13 | 2022-08-09 | University of Pittsburgh—Of the Commonwealth Systems of Higher Education | Vascular extracellular matrix hydrogel |
| EP3755267B1 (en) * | 2018-02-22 | 2024-06-12 | University of Pittsburgh - of the Commonwealth System of Higher Education | Extracts for the regeneration of ligaments |
-
2019
- 2019-10-25 EP EP19876046.4A patent/EP3870192A4/en active Pending
- 2019-10-25 CN CN201980067713.0A patent/CN112867499A/zh active Pending
- 2019-10-25 US US17/286,534 patent/US20210379245A1/en active Pending
- 2019-10-25 AU AU2019363610A patent/AU2019363610B2/en active Active
- 2019-10-25 WO PCT/US2019/058052 patent/WO2020086955A1/en not_active Ceased
- 2019-10-25 CA CA3117688A patent/CA3117688A1/en active Pending
- 2019-10-25 JP JP2021521511A patent/JP7536004B2/ja active Active
-
2024
- 2024-08-06 JP JP2024129889A patent/JP2024166198A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170049932A1 (en) * | 2014-04-24 | 2017-02-23 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fractionating Extracellular Matrix to Modulate Bioactivity and the Host Response |
| WO2018161034A1 (en) * | 2017-03-02 | 2018-09-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Extracellular matrix (ecm) hydrogel and soluble fraction thereof for the treatment of cancer |
Non-Patent Citations (3)
| Title |
|---|
| Seif-Naraghi, S.B. et al., 'Safety and Efficacy of an Injectable Extracellular Matrix Hydrogel for Treating Myocardial Infarction', Science Translational Medicine, 2013, Vol. 5, No. 173, 173ra25 & Supplementary Materials and Methods * |
| Singelyn, J.M. et al., Journal of the American College of Cardiology, 2012, Vol. 59, No. 8, pages 751-763 * |
| Singelyn, J.M. et al., 'Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering', Biomaterials, 2009, Vol 30, No 29, pages 5409-1546 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020086955A1 (en) | 2020-04-30 |
| EP3870192A1 (en) | 2021-09-01 |
| AU2019363610A1 (en) | 2021-05-13 |
| US20210379245A1 (en) | 2021-12-09 |
| CA3117688A1 (en) | 2020-04-30 |
| EP3870192A4 (en) | 2022-09-21 |
| JP2024166198A (ja) | 2024-11-28 |
| JP7536004B2 (ja) | 2024-08-19 |
| JP2022505468A (ja) | 2022-01-14 |
| CN112867499A (zh) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11648281B2 (en) | Methods for treating cardiac conditions | |
| Nguyen et al. | Developing injectable nanomaterials to repair the heart | |
| CA2900971C (en) | Serum fraction of platelet-rich fibrin | |
| JP2024166198A (ja) | 可溶性細胞外マトリックス組成物および血管内送達のための方法 | |
| US20230129268A1 (en) | Platelet rich plasma formulations | |
| EP3302594B1 (en) | Cardiac fibroblast-derived extracellular matrix and injectable formulations thereof for treatment of ischemic disease or injury | |
| Lee et al. | VEGF-attenuated platelet-rich plasma improves therapeutic effect on cartilage repair | |
| KR20120100962A (ko) | 신장 손상을 치료하는데 사용하기 위한 조혈 줄기 세포 | |
| Zhu et al. | Peripheral nerve defects repaired with autogenous vein grafts filled with platelet-rich plasma and active nerve microtissues and evaluated by novel multimodal ultrasound techniques | |
| Andreone et al. | Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial | |
| WO2017152039A1 (en) | Protection and delivery of multiple therapeutic proteins | |
| Yu et al. | Mesenchymal stem cell secretome-loaded fibrin glue improves the healing of intestinal anastomosis | |
| Li et al. | Brain-derived extracellular vesicles mediate traumatic brain injury associated multi-organ damage | |
| WO2021009659A1 (en) | Compositions for treatment of erectile dysfunction, methods for preparing the same and applications thereof | |
| Alsousou et al. | Platelet-rich plasma in regenerative medicine | |
| WO2020163766A1 (en) | Periosteal skeletal stem cells in bone repair | |
| CN101229366B (zh) | 成纤维细胞生长因子在制备促进血管生成药物中的应用 | |
| US20120258086A1 (en) | Platelet solution for use in joint surgery | |
| Pandey | Clinical limitation in stem cell therapy | |
| Liu et al. | PRP-loaded pH-responsive hydrogel for the amelioration of ventricular remodeling following myocardial infarction | |
| US20230364152A1 (en) | Compositions and methods of use for infusible extracellular matrix | |
| Spang | Intravascular infusion of a soluble extracellular matrix hydrogel therapy for acute myocardial infarction | |
| WO2024110937A1 (en) | Compositions based on a mixture of bioactive molecules and exosomes for use in the treatment of conditions requiring tissue repair and regeneration | |
| Surath | Arudra Printing | |
| US20130058916A1 (en) | Proangiogenic compositions, method for preparing same, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application | ||
| NA | Applications received for extensions of time, section 223 |
Free format text: AN APPLICATION TO EXTEND THE TIME FROM 25 OCT 2023 TO 25 MAY 2024 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED |
|
| NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 25 MAY 2024 |
|
| FGA | Letters patent sealed or granted (standard patent) |